Answers are grounded in this paper and cite their sources.
Finds inflammation control in autoimmune encephalitis, suggesting limitations for neuronal recovery.
Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti-diacylglycerol lipase alpha (DAGLA) antibody-mediated autoimmune encephalitis, achieving partial clinical remission. We now provide extended follow-up demonstrating a stable, relapse-free clinical course and persistent suppression of autoantibodies. However, the patient exhibited progressive neurodegeneration despite sustained control of B cell-mediated inflammation. This dissociation between immune quiescence and structural decline highlights that CAR T cell therapy, while highly effective in extinguishing inflammation, may not be sufficient to prevent or reverse ongoing neuronal damage in disorders characterized by both inflammation and neurodegeneration.
No takes yet. Share an insight, caveat, or question.
Mougiakakos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: